Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?

Mathieu S. Bolhuis*, Simon Tiberi, Giovanni Sotgiu, Saverio De Lorenzo, Jos G. Kosterink, Tjip S. van der Werf, Giovanni Battista Migliori, Jan-Willem Alffenaar

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

9 Citations (Scopus)

Abstract

We read with great interest the comments from D. Cattaneo and co-workers on our article describing a retrospective study in multidrug-resistant tuberculosis (MDR-TB) patients receiving linezolid tailored to the individual patient using therapeutic drug monitoring as part of their regular treatment [1]. Cattaneo and co-workers correctly summarise that one of our findings was that we did not observe any significant differences between exposure to linezolid and adverse events. Indeed, this observation may be surprising with a toxic drug like linezolid, but it is not a reason to rule out therapeutic drug monitoring as a tool for optimising the treatment regimens of TB patients. The explanation for this lies in the design of our study, the characteristics of the patient population, and the specific dosing regimen used for MDR-TB patients.
Original languageEnglish
Pages (from-to)1288-1890
Number of pages4
JournalEuropean Respiratory Journal
Volume47
Issue number4
DOIs
Publication statusPublished - Apr-2016

Keywords

  • MULTIDRUG-RESISTANT TUBERCULOSIS
  • PHARMACOKINETICS
  • TOLERABILITY
  • REGIMENS
  • RIFAMPIN
  • SAFETY

Cite this